We’re excited to announce that on Tuesday, April 24, 2018, the U.S. Food and Drug Administration (FDA) granted approval of tolvaptan (brand name JYNARQUE™, pronounced jin-AR-kew) to be the first treatment in the United States for adult patients with autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease (PKD).
Tolvaptan has shown to slow kidney function decline in adults at risk of rapidly progressing ADPKD. This treatment is an oral pill taken twice a day. It is a long-term use drug – extending the time before a patient needs dialysis or a transplant, though not curing the disease. The drug was developed by Otsuka Pharmaceuticals.
The PKD Foundation not only supported early studies that led to the development of JYNARQUE™ as a treatment but also helped guide PKD patients to the clinical trials.
“Today is an historic day in providing hope to patients with polycystic kidney disease, and we are thrilled to be a part of this first milestone to treat patients with ADPKD,” said Andy Betts, CEO of the PKD Foundation. “For the past 35 years, our goal has been to support PKD patients from care to cure. It is gratifying to play a part in the discovery of this treatment and to see it come to fruition.”
Betts added, “Many thanks to all of the patients who graciously took the time and resources to participate in the clinical trials to bring this treatment to the PKD community. This treatment would not exist without these patients.”
Questions about the new treatment? Call us at 1.800.PKD.CURE
Frequently Asked Questions (Updated 4/28)
- What will you do with the information once you have it?
- Will a diagnosis prevent you from obtaining medical or life insurance for your children? Are you better off knowing or not knowing?
- Can you financially afford the test (although ultrasound is relatively inexpensive, confirmation by genetic testing is expensive)?